Home » Stocks » KMDA

Kamada Ltd. (KMDA)

Stock Price: $6.73 USD -0.08 (-1.17%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $6.53 -0.20 (-2.97%) Jan 26, 4:26 PM
Market Cap 302.44M
Revenue (ttm) 127.19M
Net Income (ttm) 22.25M
Shares Out 40.30M
EPS (ttm) 0.48
PE Ratio 14.02
Forward PE 714.29
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $6.73
Previous Close $6.81
Change ($) -0.08
Change (%) -1.17%
Day's Open 6.84
Day's Range 6.73 - 6.89
Day's Volume 74,214
52-Week Range 4.56 - 11.73

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pa...

GlobeNewsWire - 1 month ago

REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition...

Zacks Investment Research - 2 months ago

Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.

Seeking Alpha - 2 months ago

Kamada Ltd. (KMDA) CEO Amir London on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Kamada (NASDAQ:KMDA) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 7.14% over the past year to $0.15, which beat the estimate of $0.06.

Zacks Investment Research - 2 months ago

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the t...

Seeking Alpha - 2 months ago

We believe Kamada looks cheap, as there are long-tailed asset returns from the Takeda deal which the market may be overlooking. Recent retraction in Kamada's shares on the charts signals a pot...

The Motley Fool - 3 months ago

The biotech specializes in plasma-derived protein therapeutics.

GlobeNewsWire - 3 months ago

REHOVOT, Israel, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has signed an agreement with the Israe...

GlobeNewsWire - 3 months ago

REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions wit...

The Motley Fool - 4 months ago

Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.

Other stocks mentioned: LLY
24/7 Wall Street - 4 months ago

Kamada Ltd. (NASDAQ: KMDA) took a big step in the fight against COVID-19 on Tuesday when the biopharmaceutical company announced initial interim results from its ongoing midstage coronavirus s...

GlobeNewsWire - 4 months ago

REHOVOT, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced the completion of enrollment and initial in...

Zacks Investment Research - 5 months ago

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Other stocks mentioned: CERS, TTOO
The Motley Fool - 5 months ago

Convalescent plasma holds promise for treating COVID-19, but it's still unproven.

Other stocks mentioned: ADMA, EBS
Benzinga - 5 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, CERS, GRFS, LMNL, SONN, THMO, TTOO
Benzinga - 5 months ago

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the ...

Other stocks mentioned: LMNL, SONN
GlobeNewsWire - 5 months ago

REHOVOT, Israel and FORT LEE, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA) and Kedrion Biopharma, two leading biopharmaceutical companies specialized in plasma-d...

Seeking Alpha - 5 months ago

Kamada's (KMDA) CEO Amir London on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its B...

Benzinga - 5 months ago

Shares of Kamada (NASDAQ:KMDA) moved lower by 2.5% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and ...

Benzinga - 5 months ago

On Wednesday, August 12, Kamada (NASDAQ: KMDA) will release its latest earnings report.

GlobeNewsWire - 5 months ago

REHOVOT, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that the first patient has been recruited to...

GlobeNewsWire - 5 months ago

REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...

Benzinga - 5 months ago

Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.

Other stocks mentioned: BURG, LMNL
The Motley Fool - 5 months ago

Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.

Zacks Investment Research - 5 months ago

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 6 months ago

Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety

Zacks Investment Research - 7 months ago

Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

REHOVOT, Israel, June 17, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today provided an update on its development of a pla...

Zacks Investment Research - 7 months ago

Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Kamada Ltd (KMDA) CEO Amir London on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of Kamada (NASDAQ:KMDA) were flat in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 10 months ago

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

Other stocks mentioned: RDHL, VIR
GlobeNewsWire - 10 months ago

REHOVOT, Israel, March 11, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial-stage plasma-derived biopharmaceutical company, today provided an update on progress relat...

GlobeNewsWire - 11 months ago

REHOVOT, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form ...

GlobeNewsWire - 1 year ago

Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada’s Growth Plans and Execution of Strategic Business Opportunities Execut...

Zacks Investment Research - 1 year ago

Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GlobeNewsWire - 1 year ago

REHOVOT, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomize...

GlobeNewsWire - 1 year ago

REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a bindin...

GlobeNewsWire - 1 year ago

REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical ...

Seeking Alpha - 1 year ago

Kamada Ltd. (KMDA) CEO Amir London on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Kamada (KMDA) delivered earnings and revenue surprises of 66.67% and 14.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB ® in 2017

About KMDA

Kamada develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and sna... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1990
CEO
Amir London
Employees
429
Stock Exchange
NASDAQ
Ticker Symbol
KMDA
Full Company Profile

Financial Performance

In 2019, Kamada's revenue was $127.19 million, an increase of 11.11% compared to the previous year's $114.47 million. Earnings were $22.25 million, a decrease of -0.20%.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Kamada stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 63.45% from the latest price.

Price Target
$11.00
(63.45% upside)
Analyst Consensus: Strong Buy